Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study Authors: Vincenzo Venerito, Giuseppe Lopalco, Cristiana Colaprico, Daniele Catamerò, Fabio Cacciapaglia, Florenzo Iannone Published: 2026 ABSTRACT AbstractObjectiveTo evaluate 6-month clinical outcomes in obese patients with psoriatic arthritis (PsA) who initiated tirzepatide concurrently with biologic therapy compared with those starting biologics alone.MethodsPropensity score-matched comparative study at tertiary care rheumatology centres. Patients with PsA with body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity initiating tirzepatide (2.5 mg/week, uptitrated to 5 mg/week after 1 month) with biologic therapy were prospectively enrolled from January 2025. Controls initiating biologics alone (2021–2025) were matched 1:2 on BMI, disease duration, Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI). Outcomes at 6 months included minimal disease activity, DAPSA low disease activity (≤14), PsA Impact of Disease-12 (PsAID-12) Patient Acceptable Symptom State (PASS ≤4), Health Assessment Questionnaire (HAQ ≤0.5), PASI ≤1, Visual Analogue Scale pain and C reactive protein (CRP). Continuous outcomes were additionally analysed with ANCOVA adjusted for baseline and a mixed (time × group) model.ResultsThirty-one patients completed 6 months and were matched to 62 controls. Baseline characteristics were well balanced. The tirzepatide group showed greater BMI reduction (−2.9±2.0 vs +0.4±1.2 kg/m², p<0.001) and lower CRP (4.2±3.8 vs 7.7±3.0 mg/L, p<0.001). PsAID-12 PASS was achieved by 48% vs 21% (OR 3.44, 95% CI 1.38 to 8.63, p=0.009), HAQ≤0.5 by 42% vs 18% (OR 3.27, 95% CI 1.26 to 8.44, p=0.022) and PASI≤1 by 74% vs 52% (OR 2.59, 95% CI 1.03 to 6.56, p=0.045). Baseline-adjusted ANCOVA confirmed significant 6-month differences in favour of tirzepatide for BMI, CRP, PsAID-12 and DAPSA, with a significant time × group interaction for BMI, CRP and PsAID-12.ConclusionConcurrent tirzepatide and biologic initiation in obese PsA was associated with significantly better patient-reported outcomes, skin disease control, baseline-adjusted joint disease activity and CRP reduction at 6 months. WHAT IS ALREADY KNOWN ON THIS TOPIC Obesity affects up to 45% of patients with PsA and is independently associated with reduced biologic efficacy and lower minimal disease activity (MDA) achievement. Obesity affects up to 45% of patients with PsA and is independently associated with reduced biologic efficacy and lower minimal disease activity (MDA) achievement. Glucagon-like peptide-1 receptor agonists possess immunomodulatory properties beyond metabolic effects, but their impact on PsA outcomes when combined with biologics is largely unknown. Glucagon-like peptide-1 receptor agonists possess immunomodulatory properties beyond metabolic effects, but their impact on PsA outcomes when combined with biologics is largely unknown. WHAT THIS STUDY ADDS Concurrent tirzepatide initiation with biologic therapy in obese PsA was associated with a threefold increase in PsA Impact of Disease-12 Patient Acceptable Symptom State achievement, with corresponding gains in functional status, skin disease, baseline-adjusted joint activity and C reactive protein. Concurrent tirzepatide initiation with biologic therapy in obese PsA was associated with a threefold increase in PsA Impact of Disease-12 Patient Acceptable Symptom State achievement, with corresponding gains in functional status, skin disease, baseline-adjusted joint activity and C reactive protein. The dichotomous physician-assessed targets (MDA, Disease Activity Index for Psoriatic Arthritis (DAPSA) low disease activity) did not separate significantly, but the underlying continuous joint-activity score (Disease Activity Index for Psoriatic Arthritis) improved more on tirzepatide after adjustment for baseline values, supporting a real but partly subthreshold effect. The dichotomous physician-assessed targets (MDA, Disease Activity Index for Psoriatic Arthritis (DAPSA) low disease activity) did not separate significantly, but the underlying continuous joint-activity score (Disease Activity Index for Psoriatic Arthritis) improved more on tirzepatide after adjustment for baseline values, supporting a real but partly subthreshold effect. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings support addressing obesity pharmacologically at the time of biologic initiation in PsA. These findings support addressing obesity pharmacologically at the time of biologic initiation in PsA. Introduction Obesity affects up to 45% of patients with psoriatic arthritis (PsA) and is independently associated with reduced biologic efficacy and lower minimal disease activity (MDA) achievement.1 2 Adipose tissue acts as an active endocrine organ producing proinflammatory adipokines, which sustain systemic inflammation, alter drug pharmacokinetics and increase mechanical joint loading, contributing to a treatment-refractory phenotype.3 Weight loss of ≥5% has been linked to improved tumour necrosis factor inhibitor (TNFi) response in obese PsA,4 yet pharmacological weight management remains largely unexplored as an adjunct to biologic therapy. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted considerable interest in rheumatology.5 Beyond metabolic effects, GLP-1RAs exert immunomodulatory properties including NF-κB inhibition, suppression of proinflammatory cytokines and reduction of adipose tissue macrophage infiltration with polarisation shift towards anti-inflammatory phenotypes.6 Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, achieves superior weight reduction compared with selective GLP-1 agonists,7 but evidence on its impact on PsA outcomes remains limited to one randomised trial restricted to a single biologic class.8 We report findings from a propensity score-matched study evaluating 6-month outcomes of concurrent tirzepatide and biologic initiation across various biologic classes in obese PsA. Methods Study design and population We conducted a propensity score-matched comparative study at tertiary care rheumatology centres with structured electronic health records since 2009. Patients with PsA meeting the ClASsification criteria for Psoriatic ARthritis; the standard classification criteria for psoriatic arthritis classification criteria,9 with body mass index (BMI) ≥30 kg/m² or BMI≥27 kg/m² with at least one weight-related comorbidity (in line with the approved tirzepatide indication), initiating tirzepatide (2.5 mg/week subcutaneously, uptitrated to 5 mg/week after 1 month) concurrently with biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) therapy were prospectively enrolled from January 2025. Biologic therapy was not suspended, delayed or dose-modified at tirzepatide initiation. Controls were retrospectively identified from patients with PsA meeting the same eligibility criteria who initiated b/tsDMARDs alone (2021–2025). In both arms, patients received the standard lifestyle counselling routinely provided at the participating centres, comprising generic dietary advice and encouragement of physical activity at the time of b/tsDMARD initiation; structured dietitian-led nutritional programmes or supervised exercise interventions were not added to the tirzepatide arm. Propensity scores were estimated using logistic regression including BMI, disease duration, Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI). Nearest-neighbour matching (1:2, caliper 0.2 SD of the logit) was performed without replacement. Balance was assessed using standardised mean differences (SMDs <0.1 considered adequate). Outcomes at 6 months included MDA (≥5/7 criteria),10 DAPSA low disease activity (LDA≤14), PsA Impact of Disease-12 (PsAID-12), Patient Acceptable Symptom State (PASS ≤4),11 Health Assessment Questionnaire (HAQ) ≤0.5, PASI ≤1, Visual Analogue Scale (VAS) pain and C reactive protein (CRP). Secondary outcomes included BMI change, percentage weight loss and safety. Continuous variables were compared using independent t-test or Mann-Whitney U test; categorical variables using χ2 test or Fisher’s exact test. ORs with 95% CIs were estimated by logistic regression. To address the longitudinal structure of the design, continuous outcomes were further analysed with (1) analysis of covariance; a statistical model combining ANOVA and regression to compare group means while adjusting for continuous covariates (ANCOVA) at 6 months adjusted for the baseline value, with group as factor, and (2) A mixed (split-plot) ANOVA with within-subjects factor time (baseline, 6 months) and between-subjects factor group, reporting the time × group interaction with partial η2. As a sensitivity analysis, tirzepatide patients were stratified by achievement of ≥5% body weight loss at 6 months. No formal a priori power calculation was performed; the sample size reflects the consecutively enrolled and matched obese patients with PsA available during the study window. Analyses were performed in R (V.4.3.1); p<0.05 was considered statistically significant. The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. Results Of 36 enrolled patients, 5 discontinued before 6 months: 4 due to high out-of-pocket cost (tirzepatide is not reimbursed for this indication in Italy) and 1 after 1 month due to severe nausea. The remaining 31 patients were matched to 62 controls from 332 obese patients with PsA initiating biologics alone during the study period (figure 1A). Concurrent tirzepatide and biologic therapy versus biologic alone in obese patients with PsA (n=31 vs n=62). (A) Biologic class distribution in both groups. (B) Forest plot of ORs (95% CI) for 6-month clinical outcomes; significant results (p<0.05) in red. (C) Metabolic and inflammatory changes: BMI change from baseline and 6-month CRP levels. (D) Proportion of patients achieving clinical targets at 6 months. *p<0.05, **p<0.01. BMI, body mass index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; HAQ, Health Assessment Questionnaire; JAKi, JAK inhibitor; LDA, low disease activity; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsAID PASS, PsA Impact of Disease-12 Patient Acceptable Symptom State; TNFi, tumour necrosis factor inhibitor. Baseline characteristics were well balanced after propensity score matching (table 1). Mean age was 56.1±8.2 vs 54.8±9.5 years (p=0.517), with 65% vs 61% female (p=0.940). Mean BMI was 34.4±5.5 vs 34.3±3.8 kg/m² (p=0.919), disease duration 3.8±7.0 vs 6.6±6.6 years (p=0.062), baseline DAPSA 17.1±7.9 vs 17.6±7.6 (p=0.769), PASI 2.4±3.6 vs 1.9±1.9 (p=0.382) and HAQ 1.02±0.54 vs 0.87±0.74 (p=0.319). Baseline PsAID-12 (5.7±1.6 vs 5.5±1.8, p=0.602), VAS pain (57.3±24.4 vs 63.6±21.3, p=0.211) and CRP (7.4±2.3 vs 8.3±3.7 mg/L, p=0.154) were comparable between groups. Comorbidities were similarly distributed: hypertension 68% vs 63% (p=0.818), dyslipidaemia 65% vs 61% (p=0.940) and diabetes mellitus 29% vs 24% (p=0.624). Polyarticular involvement was reported in 10/31 (32%) tirzepatide vs 18/62 (29%) control patients (p=0.936) and axial involvement in 5/31 (16%) vs 12/62 (19%) (p=0.783), confirming a comparable distribution of the dominant articular pattern between groups. Biologic class distribution was comparable between groups (TNFi 71% vs 60%, IL-17i 19% vs 26%, IL-23i 3% vs 11%, IL-12/23i 0% vs 3%, JAK inhibitor 6% vs 0%), with median biologic line 2 (IQR 2–2) vs 1 (IQR 1–2) (p=0.041) and no relevant differences in concomitant methotrexate use (32% vs 35%) or corticosteroid exposure. Table 1Baseline characteristics and 6-month outcomes (propensity score-matched)VariableTirzepatide+Bio (n=31)Biologic alone (n=62)SMDP valueAge, years56.1±8.2 (41–68)54.8±9.5 (35–79)0.1460.517Female, n (%)20 (65%)38 (61%)0.0670.940BMI, kg/m²34.4±5.5 (28–43)34.3±3.8 (30–43)0.0210.919Disease duration, years3.8±7.0 (0.1–25)6.6±6.6 (0.1–25)0.4120.062Current smoker, n (%)9 (29%)16 (26%)0.0720.806Comorbidities Any comorbidity, n (%)29 (94%)56 (90%)0.1180.714 Diabetes mellitus, n (%)9 (29%)15 (24%)0.1090.624 Hypertension, n (%)21 (68%)39 (63%)0.1020.818 Dyslipidaemia, n (%)20 (65%)38 (61%)0.0670.940Disease characteristics Polyarticular, n (%)10 (32%)18 (29%)0.0700.936 Axial involvement, n (%)5 (16%)12 (19%)0.0840.783 Psoriasis, n (%)28 (90%)55 (89%)0.0531.000Baseline disease activity DAPSA17.1±7.9 (2.4–33.0)17.6±7.6 (1.0–35.0)0.0650.769 HAQ1.02±0.54 (0.00–2.10)0.87±0.74 (0.00–2.71)0.2320.319 PASI2.4±3.6 (0.0–16.0)1.9±1.9 (0.0–13.5)0.1740.382 CRP, mg/L7.4±2.3 (3.1–14.0)8.3±3.7 (1.1–15.6)0.2920.154 PsAID-125.7±1.6 (1.1–8.1)5.5±1.8 (1.8–10.0)0.1170.602 VAS pain57.3±24.4 (0–90)63.6±21.3 (2–100)0.2750.211Treatment MTX combination, n (%)10 (32%)22 (35%)0.0680.938 Biologic line, median (IQR)2 (2–2)1 (1–2)0.2350.041Biologic class TNFi22 (71%)37 (60%)0.2370.363 IL-17i6 (19%)16 (26%)0.1540.608 IL-23i1 (3%)7 (11%)0.3110.261 IL-12/23i0 (0%)2 (3%)0.2560.551 JAKi2 (6%)0 (0%)0.3650.1096-month outcomes BMI change, kg/m²−2.9±2.0+0.4±1.2<0.001 Weight loss, kg9.4±6.1— ≥5% weight loss, n (%)29/31 (94%)— CRP, mg/L4.2±3.87.7±3.0<0.001 VAS pain33.1±19.446.4±28.30.028 MDA, n (%)8/31 (26%)10/62 (16%)0.279 DAPSA LDA (≤14), n (%)26/31 (84%)51/62 (82%)>0.99 PsAID-12 PASS (≤4), n (%)15/31 (48%)13/62 (21%)0.009 HAQ ≤0.5, n (%)13/31 (42%)11/62 (18%)0.022 PASI ≤1, n (%)23/31 (74%)32/62 (52%)0.045Continuous variables are mean±SD (min-max); categorical variables n (%); biologic line median (IQR). Min-max ranges added in this revised version.BMI, body mass index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; HAQ, Health Assessment Questionnaire; JAKi, JAK inhibitor; LDA, low disease activity; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PsAID PASS, PsA Impact of Disease-12 Patient Acceptable Symptom State; SMD, standardised mean difference; TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale. Baseline characteristics and 6-month outcomes (propensity score-matched) Continuous variables are mean±SD (min-max); categorical variables n (%); biologic line median (IQR). Min-max ranges added in this revised version. BMI, body mass index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; HAQ, Health Assessment Questionnaire; JAKi, JAK inhibitor; LDA, low disease activity; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PsAID PASS, PsA Impact of Disease-12 Patient Acceptable Symptom State; SMD, standardised mean difference; TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale. At 6 months, the tirzepatide group demonstrated significantly greater BMI reduction (−2.9±2.0 vs +0.4±1.2 kg/m², p<0.001), corresponding to a mean weight loss of 9.4±6.1 kg (−9.7%), with 29/31 patients (94%) achieving ≥5% weight loss (figure 1C). CRP was significantly lower in the tirzepatide group (4.2±3.8 vs 7.7±3.0 mg/L, p<0.001). Patient-reported outcomes consistently favoured the tirzepatide group (figure 1B,D). PsAID-12 PASS was achieved by 15/31 (48%) vs 13/62 (21%) patients (OR 3.44, 95% CI 1.38 to 8.63, p=0.009), HAQ ≤0.5 by 13/31 (42%) vs 11/62 (18%) (OR 3.27, 95% CI 1.26 to 8.44, p=0.022) and PASI ≤1 by 23/31 (74%) vs 32/62 (52%) (OR 2.59, 95% CI 1.03 to 6.56, p=0.045). VAS pain was significantly lower (33.1±19.4 vs 46.4±28.3, p=0.028). In contrast, physician-assessed composite indices did not differ significantly: DAPSA LDA was achieved by 26/31 (84%) vs 51/62 (82%) (OR 1.12, 95% CI 0.35 to 3.57, p>0.99) and MDA by 8/31 (26%) vs 10/62 (16%) (OR 1.81, 95% CI 0.65 to 5.05, p=0.279); for the latter the post hoc achieved power was 0.21. Longitudinal modelling of the continuous outcomes corroborated and refined these findings. ANCOVA, adjusting the 6-month value for the baseline, confirmed significantly larger reductions on tirzepatide for BMI (adjusted difference −3.34, 95% CI −3.97 to −2.71, p<0.001), CRP (−3.49, 95% CI −5.13 to −1.86, p<0.001), PsAID-12 (−0.85, 95% CI −1.37 to −0.32, p=0.002) and DAPSA (−1.78, 95% CI −3.22 to −0.34, p=0.016); HAQ (p=0.082), VAS pain (p=0.084) and PASI (p=0.324) showed numerically smaller adjusted differences. The mixed-model time × group interaction was significant for BMI (F(1.91)=105.8, p<0.001, η²p=0.54), PsAID-12 (F=8.42, p=0.005, η²p=0.085) and CRP (F=5.52, p=0.021, η²p=0.057), with a non-significant trend for HAQ (p=0.076). All 31 tirzepatide patients (100%) remained on the index biologic/JAK inhibitor at the 6-month visit; no patient discontinued or switched the concurrently initiated b/tsDMARD during follow-up. In the control registry no within-window biologic switch was documented either. In a sensitivity analysis within the tirzepatide arm, patients reaching the ≥5% body weight loss threshold (n=29) had numerically better PsAID-12 PASS (15/29, 52%) and MDA (8/29, 28%) achievement and a 6-month DAPSA of 9.1±5.2, compared with 0/2 PASS, 0/2 MDA and DAPSA 11.1±3.9 in the two patients who did not. Regarding tolerability, the overall tirzepatide discontinuation rate was 14% (5/36). Among the 31 completers, gastrointestinal adverse events were common but manageable: nausea in 11 (35%) and diarrhoea in 6 (19%), none leading to further discontinuation. Importantly, no patient discontinued biologic therapy, suggesting no safety signals for this combination. Discussion Concurrent initiation of tirzepatide and biologic therapy in obese PsA was associated with significantly better patient-reported outcomes at 6 months, alongside substantial weight reduction, lower CRP and a baseline-adjusted improvement in joint activity (DAPSA), while the dichotomous physician-assessed targets (DAPSA LDA, MDA) did not separate significantly in this small sample. The divergence between patient-reported outcomes and dichotomised physician-assessed targets is noteworthy. After adjustment for baseline values in ANCOVA, the underlying continuous joint-activity score was significantly lower on tirzepatide, suggesting that the comparable LDA rates partly reflect a ceiling effect at the chosen threshold rather than absent treatment effect. The 10-percentage-point absolute gap in MDA achievement (26% vs 16%) was non-significant, but the result could be consistent with a true but undetected effect (type II error) and does not support a strong negative inference. Beyond statistical power, the persistence of patient-reported symptom burden after physician-assessed remission is itself a recognised feature of PsA, fuelled by chronic widespread pain, central sensitisation, comorbid fibromyalgia and psychosocial distress that operate independently of articular inflammation; conversely, PsAID-12 captures fatigue, emotional well-being, social participation and body image,11 domains strongly influenced by obesity and responsive to weight loss,12 but not reflected in DAPSA. The near-universal achievement of ≥5% weight loss (94%) exceeds the threshold linked to improved TNFi response in obese PsA.4 Notably, the tirzepatide group was more treatment-refractory, with a significantly higher median biologic line (2 vs 1, p=0.041), yet achieved superior patient-reported outcomes. This paradox argues against a simple selection effect13 and reinforces the hypothesis that weight loss-mediated benefits operate through pathways at least partly independent of conventional disease activity. The significantly lower 6-month CRP and a significant time × group interaction in the mixed model support a direct anti-inflammatory effect of GIP/GLP-1 RA. CRP decreased from 7.4 mg/L to 4.2 mg/L in the tirzepatide group versus 8.3 mg/L to 7.7 mg/L in controls, consistent with attenuation of adipose-driven systemic inflammation beyond synovial disease.6 GLP-1RAs reduce adipose macrophage infiltration, shift macrophage polarisation towards anti-inflammatory phenotypes and decrease adipokine-driven systemic inflammation,6 supporting a metabolic-immunomodulatory mechanism that complements biologic efficacy. A recent cross-sectional cohort similarly linked metabolic load and dietary quality to PsA disease activity, with higher BMI, CRP, erythrocyte sedimentation rate and HAQ in patients with moderate-to-severe disease and low Mediterranean-diet adherence in nearly three quarters of the sample.14 Our data extend that observational signal with a prospective intervention-direction comparison. Our findings complement the randomised TOGETHER-PsA Trial (NCT06588296), which demonstrated that concomitant tirzepatide plus ixekizumab improved ACR50 and a composite endpoint including ≥10% weight reduction versus ixekizumab alone in patients with higher baseline disease burden (mean DAPSA 58.65, HAQ-DI 1.3) and higher tirzepatide doses (up to 15 mg/week).8 Two design choices differ from ours and likely contribute to the contrast between gains in continuous activity scores (significant in our cohort) and gains in dichotomous activity targets (significant in TOGETHER-PsA). First, our protocol capped tirzepatide at 5 mg/week, whereas tirzepatide produces dose-dependent reductions in body weight and dose-related, partly weight-independent reductions in CRP/IL-6; the additional 4–5 percentage points of weight loss seen at each step from 5 mg to 10 mg to 15 mg in pivotal obesity trials7 are biologically plausible drivers of further joint-disease separation, and the TOGETHER-PsA dose schedule allowed uptitration to those higher doses. Second, our cohort was less active at baseline (DAPSA 17.1 vs 58.65 in TOGETHER-PsA), leaving less room for movement on dichotomised LDA/MDA targets. Together these observations suggest that the patient-reported gains reported here reflect the conservative end of the achievable benefit, and that titrating beyond 5 mg in higher-activity disease is the rational next test. Several limitations warrant discussion. First, no formal a priori power calculation was performed; the sample size reflects available consecutively enrolled and matched obese patients with PsA during the study window, and the post hoc power for the MDA endpoint was only 0.21. Second, the small sample and single-country setting limit generalisability. Crucially, patients self-funded tirzepatide, introducing potential socioeconomic confounding: higher-income, more motivated patients may report better outcomes independently of pharmacological effect, an expectation bias that disproportionately affects patient-reported measures.15 16 Third, the prospective-retrospective hybrid design with historical controls introduces temporal confounding and possible Hawthorne effect,17 as the prospectively monitored tirzepatide group may have received more attentive follow-up; both arms received only the standard lifestyle counselling routinely provided at b/tsDMARD initiation, but a formal head-to-head equivalence of non-pharmacological care cannot be guaranteed in a non-randomised design. Fourth, despite adequate propensity score balance on matching variables, the significantly higher biologic line in the tirzepatide group (p=0.041) alongside numerically shorter disease duration (3.8 vs 6.6 years, SMD 0.412) suggests more rapid treatment escalation; while this residual imbalance would bias against the intervention group,13 it limits phenotype comparability. Fifth, 6-month follow-up may be insufficient to detect the full effect of sustained weight loss on composite disease activity indices. Sixth, the historical control registry recorded the prescribed biologic class at index and at the 6-month visit but not a continuous treatment timeline (start/stop dates, dose adjustments), so within-window biologic switching cannot be excluded with the same granularity available for the prospective tirzepatide arm; separate tender joint count/swollen joint count counts at baseline and baseline socioeconomic status were also not consistently captured for the historical controls, which may further confound patient-reported outcomes beyond the self-funding effect already noted. Notwithstanding these limitations, strengths include the real world multibiologic-class design extending evidence beyond single-class trials, rigorous propensity score matching with adequate balance, complementary longitudinal modelling that triangulates the cross-sectional results, and complete 6-month follow-up in all analysed patients with full retention of the index biologic. In conclusion, these data provide preliminary real world evidence supporting concurrent GIP/GLP-1 RA initiation with biologics in obese PsA, with significant gains on patient-reported outcomes and on baseline-adjusted joint activity and CRP, and a numerically larger but underpowered MDA signal. Addressing obesity pharmacologically at biologic initiation may represent a potential paradigm shift in managing this challenging population, warranting confirmation in larger randomised trials with extended follow-up, higher tirzepatide doses, stratification by biologic class and formal cost-effectiveness assessment.